David Jackson has been appointed president and chief executiveofficer of Affinity Biotech Inc. of Aston, Pa. He replaces AlanDickason, who has moved to the newly created position of chiefscientific officer at the company. Affinity is expected to merge withBio-Pharm Clinical Services Inc. in April, after which the operatingassets of Affinity Biotech will become a division called AffinityBiosciences. Bio-Pharm's current chief executive officer, GeraldineHenwood, will be chief executive officer of the merged company.
Osteotech Inc. of Shrewsbury, N.J., has named Richard Bauerpresident and chief executive officer, replacing Patrick McBrayer,who will continue as a company director. Bauer was president of theprosthetic implant division at Zimmer Inc., the orthopedic division ofBristol Myers Squibb.
(c) 1997 American Health Consultants. All rights reserved.